エピソード
-
Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.
-
Go online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView educational activity, based on a recent web broadcast, provides essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in curative-intent settings are shared as well. Upon completion of this accredited CE activity, participants should be better able to: Characterize the rationale for using immunotherapy as a component of multimodal therapy in locally advanced or earlier stages of non–small cell lung cancer (NSCLC), Review key clinical trials and available efficacy/safety data on immunotherapies and immune-based combinations in locally advanced and earlier stages of NSCLC, Determine the best assessment and treatment approaches for diverse populations of patients with stage I-III NSCLC as part of clinical practice or clinical trials based on the latest evidence and recommendations, effective multidisciplinary and interprofessional collaboration and care coordination, and patient needs, values, and preferences.
-
エピソードを見逃しましたか？
-
Go online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from these therapies, and thus, broad biomarker testing is essential to identify these patients, as is making the best rational therapies available to them. Many barriers to biomarker testing and appropriate biomarker-driven treatment exist, and there are also significant disparities in lung cancer clinical care and research, but effective steps can be taken to overcome them. An essential component of modern lung cancer management is patient education, which allows patients to become well-informed participants in their care and participate in shared decision-making with their multidisciplinary clinical teams. This PeerView educational activity, based on a recent web broadcast and developed in collaboration with the LUNGevity Foundation, brings together leading experts in lung cancer, patients, and advocates who engage in candid conversations and clinical consultations focused on how to navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer, and provide the best possible care to all patients. Upon completion of this accredited CE activity, participants should be better able to: Describe established, new, and emerging genomic alterations with potential for therapeutic targeting in NSCLC, Discuss the increasing importance of broad biomarker testing for clinical decision-making and the latest methods for identifying genomic alterations in NSCLC, Compare the mechanisms of action, efficacy, and safety of precision therapies targeting established, new, and emerging molecular alterations in NSCLC, Implement best practices, collaborative strategies, and shared decision-making to ensure widespread biomarker testing, precision treatment, and equitable care of diverse populations of patients with NSCLC in the context of clinical practice or clinical trials.
-
Go online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions designed to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite evidence surrounding the efficacy of regimens with novel proteasome inhibitors, immunomodulatory drugs, antibodies, targeted therapies, and cell therapies across multiple myeloma (MM) treatment settings, including smoldering MM, newly diagnosed MM, and relapsed/refractory MM, Select evidence-based regimens with novel components for the management of patients with newly diagnosed MM, Develop treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options, Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.
-
Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.
-
Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.
-
Go online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon completion of this accredited CE activity, participants should be better able to: Identify the clinical signs of AML, relevant prognostic factors, and patient- or disease-related features that influence treatment selection, Discuss efficacy and safety evidence surrounding novel cytotoxic, targeted, and epigenetic therapies for AML, Develop educational strategies for patients with AML related to therapeutic expectations, adherence, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with AML receiving novel cytotoxic, targeted, and epigenetic therapies.
-
Go online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the global disease burden, etiopathogenesis, risk factors, and stratification scores for cancer-associated VTE using established diagnostic tools, Review safety & efficacy evidence, clinical trial data, and practice guidelines for currently available treatment options for managing cancer-associated VTE, Employ guideline-concordant, evidence-based care and shared decision-making strategies including multidisciplinary and interprofessional collaboration for prevention and treatment of cancer-associated VTE in routine clinical practice.
-
Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.
-
Go online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternative asparaginase compounds. Upon completion of this accredited CE activity, participants should be better able to: Cite current, multimodal recommendations for acute lymphoblastic leukemia (ALL) management in pediatric, adolescents and young adult (AYA), and adult populations, including multi-agent chemotherapy and asparaginase compounds, antibody-based approaches, cellular therapy, and tyrosine kinase inhibitors, Discuss the clinical implications of Escherichia coli (E. coli) asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations, Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of chemotherapy for ALL, Apply updated protocols for the management of E. coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.
-
Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.
-
Go online to PeerView.com/ETX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in sleep medicine discusses recent guidelines and evidence presented at the SLEEP 2021, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, on the pharmacologic management of idiopathic hypersomnia (IH). Upon completion of this accredited CE activity, participants should be better able to: Employ currently recommended approaches and available assessment tools to identify and differentially diagnose patients with IH, Incorporate the latest guideline recommendations and evidence for approved and emerging pharmacotherapies to optimize the management of patients with IH, Evaluate the clinical potential of recent advances in the pharmacologic treatment of patients with IH.
-
Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma and unresectable, metastatic disease, Summarize evidence on novel applications of immunotherapy in melanoma, including as neoadjuvant therapy, as an adjuvant option for stage II disease, or as part of novel combinatorial approaches, Integrate immunotherapy into the management of patients with resectable and unresectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy across the spectrum of disease.
-
Go online to PeerView.com/QAM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a preeminent drug class for treating type 2 diabetes mellitus (T2DM). Mounting evidence from cardiovascular outcomes trials elevated these agents’ position in clinical guidelines because of their ability to reduce cardiovascular and renal risks, while also improving glycemic control without the burdens of hypoglycemia or weight gain. In this activity, based on a recent live web broadcast, Dr. James R. Gavin III, welcomes special guests Dr. Jens Juul Holst and Davida F. Kruger for candid conversations about the science behind GLP-1 RAs and its translation into patient-centered approaches for managing T2DM. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for the prioritization of GLP-1 RAs in current clinical guidelines for patients with T2DM, including in patients with cardiovascular or renal disease, Compare and contrast GLP-1 RAs in terms of mechanism of action, safety, efficacy, mode of administration, and glycemic and nonglycemic effects, Engage in shared decision-making with patients with T2DM to individualize therapy with GLP-1 RAs, overcome administration barriers, and improve adherence, Incorporate GLP-1 RAs into evidence-based, individualized treatment regimens as appropriate for patients with T2DM.
-
Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.
-
Go online to PeerView.com/KKH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyloidosis. Hear from Suzanne Lentzsch, MD, PhD, Mathew S. Maurer, MD, and Margaret Cuomo, MSN, FNP-C, from the Columbia University Medical Center, as they give insights on diagnostic strategies for AL amyloidosis and as they explore treatment guidelines, evidence, and safety concerns of established and novel approaches to managing AL amyloidosis. Upon completion of this accredited CE activity, participants should be better able to: Summarize the distinct clinical features, symptoms, and clinical course of light chain (AL) amyloidosis, Develop team-based diagnostic and assessment strategies that capture relevant symptoms, differentiate AL amyloidosis from other disease subtypes, and characterize disease-related complications in the heart, kidneys, skin, liver, and other organ systems, Discuss current guidelines and evidence supporting established and novel approaches to managing AL amyloidosis and related cardiac or renal dysfunction, Design team-based management plans that safely incorporate novel therapies into the management of patients with AL amyloidosis.
-
Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.
-
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
-
Go online to PeerView.com/FQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, which is based on a recent live web broadcast, two obesity experts discuss weight-loss pharmacotherapy in the context of bariatric surgery as part of practical, case-centered sessions, designed to mimic the treatment considerations faced in real-world practice and illustrate how incretin-based agents can be used to individualize long-term obesity management and improve patient outcomes. Upon completion of this accredited CE activity, participants should be better able to: Recognize the roles of treatment options used adjunct to lifestyle interventions, particularly weight-loss pharmacotherapy and surgery, in addressing obesity pathophysiology, including metabolic adaptation, Assess the available evidence on current and emerging options in incretin-based weight-loss pharmacotherapies, including long-term efficacy and safety data, Integrate incretin-based pharmacotherapy into individualized, evidence-based treatment plans for long-term obesity management.
-
Go online to PeerView.com/FJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and a unique myeloprotective agent has become available that can decrease the incidence of chemotherapy-induced myelosuppression in patients with SCLC. These developments have provided new hope to patients with SCLC, but they have also increased the urgency to diagnose and treat SCLC in a timely manner to ensure patients can derive benefits from these therapies. This activity based on a live web broadcast focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases, to illustrate how to integrate the new therapeutic options into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Describe the challenges, disparities, and latest treatment advances that have led to improvements in outcomes in small cell lung cancer (SCLC), Review the latest efficacy, safety, and biomarker data from clinical trials evaluating immune checkpoint inhibition, transcription inhibition, and other novel treatment approaches and combinations in SCLC, Apply best practices for collaboration and coordination of care among the multidisciplinary lung cancer team to optimize diagnosis, assessment, and rapid initiation of treatment, and minimize treatment-related toxicities in all patients with SCLC, Develop individualized treatment plans for patients with SCLC throughout the disease continuum in the context of clinical practice or clinical trial participation.
- もっと表示する
